BAXTER INTL INC's ticker is BAX and the CUSIP is 071813109. A total of 856 filers reported holding BAXTER INTL INC in Q2 2024. The put-call ratio across all filers is 1.37 and the average weighting 0.1%.
About BAXTER INTL INC
Baxter International Inc. is a global healthcare company that specializes in developing and manufacturing medical products and therapies. The company has a long history of innovation and has been at the forefront of developing life-saving treatments for patients around the world.
Baxter's product portfolio includes a wide range of medical devices, pharmaceuticals, and biotechnology products. The company's products are used in hospitals, clinics, and other healthcare settings to treat a variety of conditions, including hemophilia, immune disorders, kidney disease, and other chronic and acute medical conditions.
Baxter's commitment to innovation has helped the company maintain a strong position in the healthcare industry. The company invests heavily in research and development, and has a strong pipeline of new products in development.
Baxter's leadership team is also a key strength of the company. The CEO, José Almeida, has a strong track record of success in the healthcare industry, and has been instrumental in driving the company's growth and success.
Overall, Baxter International Inc. is a strong and innovative company that is well-positioned to continue delivering value to patients, healthcare providers, and investors alike. With a strong product portfolio, a commitment to innovation, and a talented leadership team, Baxter is a company that investors should keep an eye on in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2024 | $9,132 | -3.8% | 273,000 | +23.0% | 1.62% | +4.6% |
Q1 2024 | $9,488 | -1.4% | 222,000 | -10.8% | 1.55% | -4.4% |
Q4 2023 | $9,626 | +14.9% | 249,000 | +12.2% | 1.62% | +12.9% |
Q3 2023 | $8,378 | +2.7% | 222,000 | +24.0% | 1.44% | +8.9% |
Q2 2023 | $8,155 | -18.6% | 179,000 | -27.5% | 1.32% | -16.0% |
Q1 2023 | $10,018 | +13.6% | 247,000 | +42.8% | 1.57% | +13.5% |
Q4 2022 | $8,818 | -99.9% | 173,000 | +3.6% | 1.38% | -8.3% |
Q3 2022 | $8,995,000 | +0.0% | 167,000 | +19.3% | 1.51% | +12.0% |
Q2 2022 | $8,992,000 | -8.7% | 140,000 | +10.2% | 1.35% | +9.2% |
Q1 2022 | $9,848,000 | -9.7% | 127,000 | 0.0% | 1.23% | -5.1% |
Q4 2021 | $10,902,000 | +6.7% | 127,000 | 0.0% | 1.30% | +3.8% |
Q3 2021 | $10,215,000 | +54.7% | 127,000 | +54.9% | 1.25% | +50.7% |
Q2 2021 | $6,601,000 | -4.6% | 82,000 | 0.0% | 0.83% | -14.1% |
Q1 2021 | $6,916,000 | +5.1% | 82,000 | 0.0% | 0.97% | -7.9% |
Q4 2020 | $6,580,000 | +22.1% | 82,000 | +22.4% | 1.05% | +7.5% |
Q3 2020 | $5,388,000 | +18.1% | 67,000 | +26.4% | 0.98% | +14.7% |
Q2 2020 | $4,563,000 | +33.8% | 53,000 | +26.2% | 0.85% | +13.9% |
Q1 2020 | $3,410,000 | -0.5% | 42,000 | +2.4% | 0.75% | +40.9% |
Q4 2019 | $3,428,000 | -4.4% | 41,000 | 0.0% | 0.53% | -5.3% |
Q3 2019 | $3,586,000 | +6.8% | 41,000 | 0.0% | 0.56% | +3.1% |
Q2 2019 | $3,358,000 | -1.7% | 41,000 | -2.4% | 0.54% | -3.4% |
Q1 2019 | $3,415,000 | +12.8% | 42,000 | -8.7% | 0.56% | +14.0% |
Q4 2018 | $3,028,000 | -14.6% | 46,000 | 0.0% | 0.49% | +4.0% |
Q3 2018 | $3,546,000 | +4.4% | 46,000 | 0.0% | 0.48% | +5.6% |
Q2 2018 | $3,397,000 | -3.3% | 46,000 | -14.8% | 0.45% | +0.7% |
Q1 2018 | $3,512,000 | +0.6% | 54,000 | 0.0% | 0.45% | +0.4% |
Q4 2017 | $3,491,000 | +3.0% | 54,000 | 0.0% | 0.44% | +1.8% |
Q3 2017 | $3,389,000 | -15.2% | 54,000 | -18.2% | 0.44% | -13.8% |
Q2 2017 | $3,996,000 | -7.9% | 66,000 | +10.0% | 0.51% | -13.5% |
Q2 2014 | $4,338,000 | -13.3% | 60,000 | -11.8% | 0.59% | -14.5% |
Q1 2014 | $5,003,000 | -6.6% | 68,000 | -11.7% | 0.68% | -10.7% |
Q4 2013 | $5,355,000 | +31.5% | 77,000 | +24.2% | 0.77% | +22.7% |
Q3 2013 | $4,073,000 | -2.0% | 62,000 | +3.3% | 0.62% | -6.2% |
Q2 2013 | $4,156,000 | – | 60,000 | – | 0.67% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Soditic Asset Management LLP | 147,620 | $7,951,000 | 9.91% |
NUANCE INVESTMENTS, LLC | 5,429,702 | $292,444,000 | 6.51% |
Endurant Capital Management LP | 245,093 | $13,201,000 | 4.30% |
Veritas Asset Management LLP | 8,589,401 | $462,625,000 | 3.83% |
GENERATION INVESTMENT MANAGEMENT LLP | 11,876,040 | $639,644,000 | 3.80% |
Sivik Global Healthcare LLC | 120,000 | $6,463,000 | 3.59% |
KINGDON CAPITAL MANAGEMENT, L.L.C. | 480,500 | $25,880,000 | 3.31% |
Integral Health Asset Management, LLC | 300,000 | $16,158,000 | 3.14% |
Boothe Investment Group, Inc. | 89,078 | $4,798,000 | 3.11% |
Glenview Capital Management | 2,257,019 | $121,563,000 | 3.04% |